Direct Methanol Fuel Cell Artificial Heart Power Supply

直接甲醇燃料电池人工心脏电源

• 批准号: 6404309
• 负责人: ALAN J CISAR
• 金额: $ 39.2万
• 依托单位: LYNNTECH, INC.
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-08-01 至 2003-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6404309
• 关键词: auxiliary heart prosthesis; biomaterial development /preparation; biomedical device power system; biomedical equipment development; circulatory assist; energy source; implant; medical implant science; methanol

DESCRIPTION (provided by applicant): Cardiovascular disease is a leading cause of death around the world. Its prevalence is growing with congestive heart failure (CHF) representing the biggest proportion. Current treatment for end-stage CHF is transplantation, but of 40,000 patients in the US under age 65, less than 3,000 will receive transplants in any year. Most patients die while waiting for a transplant. Ventricular assist devices can help some patients as a bridge to transplantation. Implantable artificial hearts will help others, and serve as a permanent solution for patients with rejection problems. For these patients to have a near-normal life requires a compact, high energy density storage system so they can move about freely. Phase I of this SBIR project demonstrated the efficacy of direct methanol fuel cells (DMFCs) in this role. DMFCs consume high energy density methanol solutions (600 Wh/L for a 10 percent solution) at temperatures slightly above ambient and deliver electrical power. DMFC stacks were demonstrated to start at room temperature, heat to operating temperature, and reliably supply electricity with a power density of 53 mW/cm_, requiring only a small fan to supply air and a small pump to deliver fuel as its balance of plant. The stack used to collect this data was fabricated from lightweight materials using standard industrial processes to insure that the final power supply resulting from this project will be manufacturable. PROPOSED COMMERCIAL APPLICATION: Nearly 500,000 people die from congestive heart failure in the US each year, with the total exceeding 3,000,000 around the world. At least half of them could benefit from a TAH or a VAD. These devices are currently in advanced stages of testing with secondary batteries as their only power supply. As they come into wider use higher energy density power supplies will be needed to give these patients a more normal life. This is the market that the proposed power supply addresses.

描述（由申请人提供）：心血管疾病是主要原因 世界各地的死亡。它的患病率随着充血性心脏的增加而增加 失败（瑞士法郎）所占比例最大。目前的治疗方法为 终末期 CHF 需要移植，但美国有 40,000 名未成年患者 65 岁，每年接受移植手术的人数均少于 3,000 人。大多数患者死亡 在等待移植的过程中。 心室辅助装置可以作为桥梁帮助一些患者 移植。植入式人造心脏将帮助他人，并作为 永久解决排斥反应问题的患者。对于这些患者来说 拥有接近正常的生活需要紧凑、高能量密度的存储系统 这样他们就可以自由行动。该 SBIR 项目的第一阶段展示了 直接甲醇燃料电池（DMFCs）的功效就在于此。 DMFC消耗高 甲醇溶液的能量密度（10% 溶液为 600 Wh/L） 温度略高于环境温度并提供电力。 DMFC 堆栈 被证明可以在室温下启动，加热到工作温度， 可靠供电，功率密度为53 mW/cm^，要求 只有一个小风扇供气和一个小泵输送燃油作为平衡 的植物。用于收集这些数据的堆栈是由轻量级制造的 使用标准工业流程的材料，以确保最终的功率 该项目产生的供应将是可制造的。 拟议的商业应用： 美国每年有近 50 万人死于充血性心力衰竭，全球总人数超过 300 万人。其中至少一半可以从 TAH 或 VAD 中受益。这些设备目前正处于测试的高级阶段，以二次电池作为唯一的电源。随着它们的广泛使用，将需要更高能量密度的电源来让这些患者过上更正常的生活。这就是所提议的电源所针对的市场。